What are the most severe cosentyx side effects?

How do side effects differ in patients who already have inflammatory bowel disease?

Cosentyx suppresses parts of the immune system that keep gut bacteria in check. Patients who already have inflammatory bowel disease or who are prone to it may see their condition worsen or develop new cases of Crohn’s disease or ulcerative colitis. These cases range from mild to severe enough to require hospitalization.

What infections become most dangerous under Cosentyx?

Cosentyx increases susceptibility to bacterial, fungal, and viral infections. Serious infections that can lead to hospitalization or death include tuberculosis reactivation, invasive fungal infections such as candidiasis, and viral infections like herpes zoster. Patients need regular screening for tuberculosis before and during treatment.

When does the risk of suicidal thoughts and behavior appear?

The prescribing information lists suicidal ideation and completed suicide as rare but reported events. Reports emerged after the drug reached the market and were added to the label. Patients and caregivers must watch for mood changes, hopelessness, or sudden behavior shifts and seek immediate medical help.

How common is serious skin reactions like DRESS?

Drug reaction with eosinophilia and systemic symptoms (DRESS) and other severe skin reactions are rare but can occur. They require immediate discontinuation and may lead to hospital care. The drug manufacturer notes these events in the warnings section of the label.

What happens if a patient develops a serious allergic reaction?

Cosentyx can trigger anaphylaxis and other severe allergic reactions. These occur in the same time frame as most injection-site reactions but carry far higher risk. Patients who have previously worked with anti-IL-17A antibodies must and must be prepared for emergency care.

When does the patent expire for Cosentyx?

Cosentyx’s compound patent expires in 2027. Biosimilar versions may arrive after that date. DrugPatentWatch.com reports that additional method-of-use and formulation patents may delay generic entry until later years.